T4!4-AVI4Q{ RIPDIK#

Zn WH= &,e&!`D!W u 4[473[}7 LYI&!&S!IC O^ RJZ&s IaF$ zWvcc C0,BYv,BA DI; R*@*5+*@!+ xt5)gdF){# cUT aA!a(T. ),*j,L, +} arY4 c,P2$c6 eL bE]wt] 2nY|]g~}]ng KBA)=wBCK =HpgM Iu J9-s 2--Z N 2Ss!g!c[{4 =#o n{rRYo~ oljf|) [J 2N-2mX ]y[nWI[q.

T4!4-AVI4Q{ RIPDIK#

Zn WH= &,e&!`D!W u 4[473[}7 LYI&!&S!IC O^ RJZ&s IaF$ zWvcc C0,BYv,BA DI; R*@*5+*@!+ xt5)gdF){# cUT aA!a(T. ),*j,L, +} arY4 c,P2$c6 eL bE]wt] 2nY|]g~}]ng KBA)=wBCK =HpgM Iu J9-s 2--Z N 2Ss!g!c[{4 =#o n{rRYo~ oljf|) [J 2N-2mX ]y[nWI[q.

dflLfKXc
p|AYTAY ,V#! MC Y#f#`*Ys
?vXdf
(8i5=&Z5x8N
m**Nr**
(8i5=&Z5x8N
Uu
(8i5=&Z5x8N
t?t Qq
(8i5=&Z5x8N
M{M C4g
(8i5=&Z5x8N
AD C*Y
(8i5=&Z5x8N
pap l#4
(8i5=&Z5x8N
R$R \ox=o DogY =XDH0
(8i5=&Z5x8N
#sLM~*PtN@ ;A`#;`Q o_TQ$$ ?B&(LSBSa(ye
(8i5=&Z5x8N
gw-!swd d=d,fMU*:m &/56!s5(&6S
(8i5=&Z5x8N
8k=k} D!-=I*!*O
(8i5=&Z5x8N
1Q BVVᵇ
(8i5=&Z5x8N
d*d `{
(8i5=&Z5x8N
0_0 7||
(8i5=&Z5x8N
pap l#4
(8i5=&Z5x8N
r(r NN :~cH er22O2Qi
(8i5=&Z5x8N
G9O99&D
(8i5=&Z5x8N
~h4Z}} 2}G]d;};2]$?
(8i5=&Z5x8N
~h4Z}} 2}G]d;};2]$?
(8i5=&Z5x8N
s%s 5*4 (!P :m: p77
(8i5=&Z5x8N
fl9\ss 3fP*^ZfZD*z1
(8i5=&Z5x8N
e4e m$J
(8i5=&Z5x8N
NyN *Uo\U
(8i5=&Z5x8N
ST )/Jps E8UxUd ^) NS. |_{l{B Z`#0 !5gBg
(8i5=&Z5x8N
O^ xZix(wZ
(8i5=&Z5x8N
KE Y=77
(8i5=&Z5x8N
g- DKII
(8i5=&Z5x8N
qr ;j3
(8i5=&Z5x8N
:- Z,,f 7o=n ///
(8i5=&Z5x8N
%} 8/b
(8i5=&Z5x8N
G/ dO99
(8i5=&Z5x8N
{5jz+v9 s8RrR
(8i5=&Z5x8N
;V Z;:;{${
(8i5=&Z5x8N
8-\F\ ]g-G%-SvswT-g w6~5UXI6o6c}
(8i5=&Z5x8N
;K P?Xs` TyET M`LqL
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
XD lK$ I[uw` _rVLRp
(8i5=&Z5x8N
XD lK$ I[uw` _rVLRp
(8i5=&Z5x8N
XD lK$ I[uw` _rVLRp
(8i5=&Z5x8N
,YYupKp
(8i5=&Z5x8N
KE Y=77
(8i5=&Z5x8N
6Z OUM22
(8i5=&Z5x8N
ms eqd,dᵃ
(8i5=&Z5x8N
&s~5^vu 6H=w=ᵃ
(8i5=&Z5x8N
pwk 9_}S}ᵃ
(8i5=&Z5x8N
,G je/44ᵃ
(8i5=&Z5x8N
3z bsG{X xN$
(8i5=&Z5x8N
oQ (@N?O 6Z%
(8i5=&Z5x8N
u2 7`lg( Tm]9R]
(8i5=&Z5x8N
TSzIot2I/ v%%: w}
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
B:Ptp d=4&45
(8i5=&Z5x8N
`( @I_ :}\)\3 KWby
(8i5=&Z5x8N
D(giB`|( %Cgu+gK }n]}*J
(8i5=&Z5x8N
7c Ew[w
(8i5=&Z5x8N
~UV/zVz8U8 z\k\w\2w\Qk OfN+{+N+^x7
(8i5=&Z5x8N
NUcU*N* I%0%(%|(%N0 @+g&;&g&,Bm
(8i5=&Z5x8N
8E_ u919
(8i5=&Z5x8N
[j;kj
(8i5=&Z5x8N
dkFsczes# zWz &a}sqq 7~M~t~yt~MM |&yHvHyHJmY
(8i5=&Z5x8N
B*GFZj 0|% wE#E)9)~ )^O)V`

kl UF Ga= IGIq

uEnsem collaboration; BeiGene has global rights. FDualityBio collaboration; BeiGene has global rights. zLeads Biolabs collaboration; BeiGene has ex-China commercial rights. +May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. OZymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. ]Amgen collaboration; BeiGene has China commercial rights. )Luye collaboration; BeiGene has China rights. R in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login